Biotronik touted positive early findings from a 1st-in-man trial of its absorbable metal stent, but researchers say the device need isn't as efficient as it could be.

Biotronik logo

German medical device maker Biotronik touted early findings from a 1st-in-man study of its Dreams absorbable drug-eluting stent, with researchers reporting a mixed bag of findings for the device.

The Dreams stent proved safe at 1 year following the procedure, but wasn't up to par with some rival devices, researchers noted.